1) myeloproliferative disorders
骨髓增殖性疾病
1.
Objective: Our purpose was to investigate if there are spontaneous megakaryocyte growth in liquid culture in vitro in patients with myeloproliferative disorders (MPD) who had spontaneous megakaryocyte colony (CFU MK) formation.
目的 :观察有自发性巨核细胞集落 (CFU MK)形成的骨髓增殖性疾病 (MPD)患者 ,其液体培养是否也有自发性巨核细胞生长。
2.
Objective:To detect the JAK2V617F mutation in myeloproliferative disorders (MPD)by allele-specific primer polymerase chain reaction and evaluate the significance of JAK2V617F in diagnosis and therapy of MPD.
目的:对bcr/abl融合基因阴性的骨髓增殖性疾病(myeloproliferativedisorders,MPD)病人进行JAK2V617F点突变定性检测,探讨bcr/abl融合基因阴性MPD的主要分子致病机制和诊断指标,为临床诊断、治疗提供理论依据。
3.
Objective:To detect the JAK2V617F mutation in myeloproliferative disorders(MPD) of Qinghai province by allele-specific primer polymerase chain reaction and evaluate the significance of JAK2V617F in diagnosis and therapy of MPD.
目的:对青海省bcr/abl融合基因阴性的骨髓增殖性疾病(myeloproliferativedisorders,MPD)病人进行JAK2V617F点突变定性检测,分析JAK2V617F点突变在我国西部地区MPD病人中的表达率,为临床诊断、治疗提供理论依据。
2) Myeloproliferative disease
骨髓增殖性疾病
1.
Objective:To observe the therapeutic effect of integrated traditional Chinese and Western medicine treatment on atheroangitis diseases caused by myeloproliferative diseases Methods:Twenty five patients were treated by integrated traditional Chinese and western medicine for 2 to 3 courses.
目的 :观察骨髓增殖性疾病 (myeloproliferativediseases ,MPD)所致动脉栓塞性疾病 (atheroangitisdiseases,AAD)的中西医结合治疗效果。
2.
In order to investigate the frequency of MPLW515L and JAK2V617F point mutations of the patients with myeloproliferative disease(MPD) in Nanjing area,MPLW515L and JAK2V617F point mutations were simultaneously detected by alleles specific polymerase chain reaction(AS-PCR) and sequencing in 190 MPD patients.
为了探讨MPLW515L和JAK2V617F点突变在南京地区骨髓增殖性疾病(MPD)中的突变情况,采用等位基因特异性聚合酶链反应(AS-PCR)及基因测序方法检测190例MPD患者的MPLW515L和JAK2V617F点突变。
3.
Chronic myeloproliferative disease (CMPD) is a group of malignant blood disorders including polycythemia vera,essential thrombocythemia,primary myelofibrosis,chronic myeloid leukemia,and so on.
慢性骨髓增殖性疾病(chronic myeloproliferative disease CMPD)是一组骨髓增殖性的恶性肿瘤,包括真性红细胞增多症,原发性血小板增多症,原发性骨髓纤维化和慢性髓系白血病等,其特征是一系或多系造血细胞的异常增生。
3) Myeloproliferative disorder
骨髓增殖性疾病
1.
JAK2 V617F mutation in BCR-ABL negative patients with myeloproliferative disorder and its clinic significance
BCR-ABL阴性骨髓增殖性疾病患者JAK2 V617F突变的检测及其临床意义
2.
The key molecular events in the pathogenesis of myeloproliferative disorders(MPD) have been poorly defined to date,except the case of chronic myeloid leukaemia with the associated rearranged gene bcr/abl.
骨髓增殖性疾病(myeloproliferative disorders,MPD)中已明确bcr-abl是慢性粒细胞白血病发病的关键环节,但bcr-abl阴性MPD发病的分子机制研究进展缓慢。
4) myeloproliferative diseases
骨髓增殖性疾病
1.
Clinical study of homoharringtonine and low-dose cytarabine in myeloproliferative diseases
高三尖杉酯碱联合小剂量阿糖胞苷治疗骨髓增殖性疾病疗效观察
2.
Objective: To discuss the clinical manifestations and laboratory characteristics of myeloproliferative diseases(MPD) in our hospital, and explore their complications, mutual transformation and prognosis, we analyzed 126 cases of myeloproliferative disorders, while compared with clinical data at home and abroad, in order to guide the early diagnosis and effective therapy.
目的:通过对126例骨髓增殖性疾病(MPD)进行临床资料分析,同时与国内外的临床资料进行对比,进一步探讨本地区骨髓增殖性疾病的发病情况,临床表现及实验室检查的特点,了解其并发症、相互转化及转归,为早期诊断及有效治疗提供依据。
3.
Objective To detected JAK2V617F point mutation and the expression levels of the KLF4 mRNA of myeloproliferative diseases.
目的检测骨髓增殖性疾病(MPDs)中JAK2 V617F点突变与锌指蛋白转录因子(KLF4 mRNA)表达,探讨JAK2 V617F点突变与KLF4 mRNA表达水平与BCR/ABL阴性的MPDs的关系。
5) MPD
骨髓增殖性疾病
1.
The discovery of JAK2V617F point mutation is an important breakthrough for understanding of molecular mechanism of BCR-ABL negative MPD,especially PV.
骨髓增殖性疾病(MPD)中除慢性粒细胞性白血病(CML)发病机制已明确外,真性红细胞增多症(PV),原发性血小板增多症(ET),原发性骨髓纤维化(IMF)等BCR-ABL阴性的MPD均尚不明确。
2.
Objective: Myeloproliferative disorders (MPD) are clonal disorders characterized by excess proliferation of cells from one or more myeloid lineages.
目的:骨髓增殖性疾病(myeloproliferative disorders,MPD)是骨髓细胞克隆性或肿瘤性增殖的疾病,包括属于慢性骨髓增殖性疾病(CMPD)范畴的慢性粒细胞白血病(CML)、真性红细胞增多症(PV)、原发性血小板增多症(ET)、慢性特发性骨髓纤维化症(CIMF)、慢性中性粒细胞白血病(CNL)及慢性嗜酸性粒细胞白血病(CEL)和属于骨髓增生异常/骨髓增殖性疾病(MDS/MPD)范畴的不典型慢粒(aCML)、慢性粒-单核细胞白血病(CMML)及幼年型粒。
6) chronic myelop-roliferative diseases (cMPDs)
慢性骨髓增殖性疾病(cMPDs)
补充资料：骨髓增殖性疾病
| 骨髓增殖性疾病 myeloproliferative diseases 一组造血干细胞肿瘤增生性疾病，在骨髓细胞普遍增生的基础上有一个系列细胞尤其突出，呈持续不断的过度增殖。临床上根据增生为主细胞系列的不同分为4种：①以红细胞系增生为主者称真性红细胞增多症。②以粒细胞系增生为主者称慢性粒细胞性白血病(CML）。③以巨核细胞系增生为主者称原发性血小板增多症。④以原纤维细胞增生为主者称原发性骨髓纤维化症。本组疾病原因未明，多见于中老年人。CML见白血病。下面介绍另3种。 真性红细胞增多症 是不明原因的全身红细胞总量明显地高于正常，俗称多血症，30％病人并发骨髓纤维化，最后引起骨髓衰竭，约10％病人演变成急性白血病。本病起病缓慢，由于循环中红细胞和血液粘稠度均增高，则引起头痛头晕，有的可发生出血和血栓。可有血压增高和脾肿大，外周血血红蛋白高达18～23克／分升，血球压积55％～80％，同位素测定红细胞容量增加（每千克体重男≥36毫升，女≥32毫升），血氧饱和度＞92％，除外其他继发性红细胞增多症后即可诊断。放血为方便易行的对症疗法，可在短期内使血容量降至正常，放射性核素磷或羟基脲和马利兰均有明显疗效。 原发性血小板增多症 较少见，其特征是血小板显著增多，伴有出血或血栓形成。男女发病率为2∶1。8％病人发生骨髓纤维化，10％病人演变成急性白血病。本病起病缓慢，脾脏可肿大，外周血血小板计数持续增高超过600×109／升，而血小板粘附、聚集和第3因子功能可减低，除外其他骨髓增殖性疾病和反应性血小板增多后即可诊断。血小板计数＞1000×109／升，合并出血者，可用单采机迅速除去血中过多的血小板，羟基脲、马利兰或23磷有满意疗效。 原发性骨髓纤维化症 是病因不明的骨髓弥漫性纤维组织增生症，伴有髓外造血（或称髓样化生），主要在脾脏，也可在肝和淋巴结。一般认为髓样化生不是骨髓纤维化的代偿作用，而是骨髓增殖的一种表现。本症的特点是起病隐袭，病程可长达10年以上，有进行性明显肿大的脾脏，有时全腹均被脾脏占据；因髓外造血使外周血中出现幼稚红细胞、幼稚粒细胞及泪滴样红细胞；骨髓因纤维化而穿刺困难，常取不出骨髓即“干抽”，骨髓活检可确定诊断。尚无根治方法，主要是对症和支持治疗，巨脾出现压迫症状、功能亢进或破裂等可切除，用罗钙全(1，25(OH）2D3）治疗纤维化收到一定疗效，同时应注意血钙升高。本症死亡原因为骨髓衰竭或无关疾病如心血管疾病等，约10％～20％病人最终变成急性白血病。 |
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条